CH-Alpha®

A New Strategy in
the Management of
Chronic Joint Symptoms

© 2012 GELITA Health GmbH. Any copies need to be authorized by GELITA

Agenda

GELITA – The company

Osteoarthritis and joint pain
CH-Alpha – The product
Pre-clinical data / Mode of action
Clinical studies

© 2012 GELITA Health GmbH. Any copies need to be authorized by GELITA

GELITA – The company

GELITA AG is world market leader in

the production Collagen Peptides.
Privately owned by founding families
Headquarter is Eberbach, near
Heidelberg, in Germany
More than 20 sites worldwide
2,600 employees
GELITA Health GmbH is the
holding company for GELITA’s
consumer activities and
markets CH-Alpha®.
Production
Sales Office

© 2012 GELITA Health GmbH. Any copies need to be authorized by GELITA

Scientific research

GELITA has been initiating and supporting scientific research about

the effect of special collagen peptides (FORTIGEL®) on joint
cartilage for 30 years.

In 2003 the GELITA Health Initiative (GHI) was founded to

professionally coordinate and promote all activities in the “joint
health” area.

The findings obtained from this research are disseminated to

physicians, nutritionists, patients and consumers worldwide by e.g.
Participation in international and national medical congresses
Presentation of new study results at scientific symposia
Development and distribution of information material about „Collagen
Peptides and joint health"

© 2012 GELITA Health GmbH. Any copies need to be authorized by GELITA

Pre-clinical research at the Collagen Research Institute

The Collagen Research Institute (CRI) is an

independent institute in Kiel, Germany, that
cooperates with numerous national and
international partners. Head of the CRI is
Dr. Steffen Oesser.

Main focus of the research is the examination of

the mode of action of collagen peptides as well as
the support of the clinical research for the therapy
of degenerative joint diseases.

© 2012 GELITA Health GmbH. Any copies need to be authorized by GELITA

 Osteoarthritis and joint pain

© 2012 GELITA Health GmbH. Any copies need to be authorized by GELITA

What is osteoarthritis?

Degenerative joint disease with wear and tear of joint cartilage.

Slow and ongoing course of disease,

often without symptoms in the beginning.

Inflammatory process often starts later.

Patients notice pain at a later stage.

© 2012 GELITA Health GmbH. Any copies need to be authorized by GELITA

Healthy Joint Cartilage

© 2012 GELITA Health GmbH. Any copies need to be authorized by GELITA

Cartilage Degeneration

© 2012 GELITA Health GmbH. Any copies need to be authorized by GELITA

Reasons for the development of osteoarthritis

age
malnutrition (overweight)
lack of physical activity
deformations of the joints
genetic predisposition
metabolic dysfunctions
burden of sports or work

© 2012 GELITA Health GmbH. Any copies need to be authorized by GELITA

Osteoarthritis: The symptoms

pain when in motion

morning stiffness
pain at rest
permanent pain
Impaired mobility of the joints

© 2012 GELITA Health GmbH. Any copies need to be authorized by GELITA

Osteoarthritis: Therapy?

Despite intensive research, there is no cure for osteoarthritis.

Analgesics and anti-inflammatory drugs only suppress the pain or the

inflammatory processes!

Because of...
increasing number of patients
the severe mental trauma
and the immense socio-economic costs

… every promising alternative to prevent

and treat osteoarthritis should be considered.

CH-Alpha® offers a solution!

© 2012 GELITA Health GmbH. Any copies need to be authorized by GELITA

Evolution in Joint Care Therapy

Pain killers and anti-inflammatory medicine:

FIRST Addressed symptoms and some short term relief and improved mobility
GENERATION

Chondroitin and Glucosamine:

SECOND Anti-inflammatory effect and pain relief
GENERATION Suggested to stimulate proteoglycan synthesis

CH-Alpha®
Evidence of collagen AND proteoglycan synthesis, exerting an effect on
THIRD total cartilage mass
Counteracting causes AND symptoms of cartilage degeneration
GENERATION
Improving physical performance & mobility

© 2012 GELITA Health GmbH. Any copies need to be authorized by GELITA

 The product

14 © 2012 GELITA Health GmbH. Any copies need to be authorized by GELITA

Mode of action

Absorption Distribution Stimulation

© 2012 GELITA Health GmbH. Any copies need to be authorized by GELITA

 Mode of action

Cartilage composition

Stimulation with CH-Alpha®

~ 25% Proteoglycans

Cartilage Cell
Amino Acids (Chondrozyt)

~ 70% Collagen
Increased Production of
Collagen and Proteoglycans

Cells & Proteoglycans

Miscellaneous Collagen

Increase of Cartilage Mass

CH-Alpha affects 95% of joint cartilage.

© 2012 GELITA Health GmbH. Any copies need to be authorized by GELITA

Pre-clinical evidence

© 2012 GELITA Health GmbH. Any copies need to be authorized by GELITA

Retain healthy joints

© 2012 GELITA Health GmbH. Any copies need to be authorized by GELITA

CH-Alpha®: Clinical Studies

Scientifically validated in numerous international pre-clinical and

clinical studies (over 2,800 patients)

Investigator Published Subjects Study design

Krug 1979 193 open
Götz 1982 60 open
Oberschelp 1985 154 comparative
Seeligmüller 1989 356 open
Adam 1991 81 double-blind, crossover
Seeligmüller 1993 519 open
Beuker, Eck 1996 40 open
Beuker, Rosenfeld 1996 100 double-blind
Moskowitz 2000 389 double-blind
Rippe 2004 250 double-blind
Rippe 2005 102 randomized
Flechsenhar, Alf 2005 100 open
Clark 2008 147 double-blind
McAlindon 2011 30 double-blind

© 2012 GELITA Health GmbH. Any copies need to be authorized by GELITA

 PennState University Study (2008) Confirms
Joint Health Effect in Healthy Athlete Students

Design:
Randomized, double blind, placebo controlled
147 individuals with joint pain or joint discomfort
(student athletes)
Therapy: CH-Alpha or placebo
24 weeks trial
pain, mobility, flexibility, different joints

Results
Significant improvements in joint problems
especially when suffering from knee arthralgia
Increase of physical performance & mobility
Decrease of alternative therapies (massages, ice
packs) Clark et al. (2008) Current Medical Research and Opinion
14, 5 / 1485 - 1496

* FORTIGEL®

© 2012 GELITA Health GmbH. Any copies need to be authorized by GELITA

 Harvard University / Tufts Medical Center Study
(2011) Visualized the Joint Health Effect of
CH-Alpha®

Design:
Prospective, randomized,
double blind, placebo controlled
30 individuals with mild grade of
Osteoarthritis (Kellgrean grade 1 – 2)
Therapy: CH-Alpha or placebo
11 months trial
dGEMRIC data

Results
Proteoglycan density in the
knee joint cartilage was
significantly increased after
CH-Alpha treatment

* FORTIGEL®

© 2012 GELITA Health GmbH. Any copies need to be authorized by GELITA

Conclusion

A growing number of clinical studies support the efficacy of

CH-Alpha treatment in OA patients and active people suffering from
joint problems

© 2012 GELITA Health GmbH. Any copies need to be authorized by GELITA

CH-Alpha® Benefits

CH-Alpha® stimulates the cartilage cells (Chondrocytes) to

produce more Collagen and Proteoglycans (95% of cartilage
mass).
As a result individuals suffering from joint problems caused by the
wear and tear of joint cartilage (Osteoarthritis) benefit by an
improved quality of life
pain reduction
improved mobility
reduced need of analgesics.

In other words:
CH-Alpha® works on the cause of the problem and not only on
the symptoms like many other products.

© 2012 GELITA Health GmbH. Any copies need to be authorized by GELITA

Facts about CH-Alpha®

Dietary supplement for healthy joints

Ready-to-drink or as micro-powder mix
Optimized structure to support cartilage regeneration
Highly convenient through:
Readily dosed
Simple intake

© 2012 GELITA Health GmbH. Any copies need to be authorized by GELITA

Safety

Dosage: no effects of over-dosing

Side effects: virtually none

Interaction with other food or medications: not known

GRAS (Generally Recognized As Safe) status from FDA

Toxicity: none

© 2012 GELITA Health GmbH. Any copies need to be authorized by GELITA

 „Pain has gone and I feel
good again!“

© 2012 GELITA Health GmbH. Any copies need to be authorized by GELITA